Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 20 de 47
Filter
1.
Oral Dis ; 2022 Jul 24.
Article in English | MEDLINE | ID: covidwho-1956788
2.
Am J Trop Med Hyg ; 107(1): 217, 2022 06 13.
Article in English | MEDLINE | ID: covidwho-1954470

Subject(s)
COVID-19 , Humans , Mortality , SARS-CoV-2
3.
J Affect Disord ; 314: 124-125, 2022 Jul 13.
Article in English | MEDLINE | ID: covidwho-1926590
4.
Int J Infect Dis ; 118: 167-168, 2022 May.
Article in English | MEDLINE | ID: covidwho-1907173

ABSTRACT

We retrieved data from the online database of the Italian Ministry of Health concerning the previous and ongoing waves of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) epidemic in Italy. We analyzed the prevalence of variants, the number of SARS-CoV-2 diagnoses, hospitalization, and intensive care unit (ICU) admissions for patients with coronavirus disease 2019 (COVID-19). We compared 2 similar days: January 12, in 2021and 2022. Although the number of positive cases in 2022 was nearly fourfold higher compared with the same period in 2021, presumably owing to higher transmissibility of Omicron variant, a considerable decrease of COVID-19 related hospitalizations (-82%) and ICU admissions (-84%) could be observed in the more recent period, when the Omicron variant was largely prevalent and COVID-19 vaccination was widespread.


Subject(s)
COVID-19 , SARS-CoV-2 , COVID-19/epidemiology , COVID-19/prevention & control , COVID-19 Vaccines , Humans , SARS-CoV-2/genetics , Vaccination
5.
EuropePMC; 2022.
Preprint in English | EuropePMC | ID: ppcovidwho-338498

ABSTRACT

Background: There is emerging evidence that headache may be a frequent common symptom in patients diagnosed with coronavirus disease 2019 (COVID-19), thus paving the way to further epidemiological studies to better evaluate this potential association. Methods: : We conducted an electronic search in Google Trends with the keyword “headache” (i.e., “mal di testa”, in Italian), with the geographical area set to “Italy” and the search period comprised between February 2020 and June 2022. The number of new weekly diagnoses of COVID-19 was also captured using the official statistics published by the Italian Ministry of Health. The potential association between Google searches for headache and new COVID-19 diagnoses was verified with Spearman’s correlation. Results: : The number of new COVID-19 diagnoses and Google searches for headache in Italy followed a similar trend, nearly overlapping, and yielding a significant correlation during the same week (r=0.56;95%CI, 0.42-0.67;p<0.001). An even better correlation was found when the number of new COVID-19 diagnoses was correlated with the Google searches for headache in the preceding week (r=0.60;95%CI, 0.47-0.70;p<0.001). Conclusion: Web interest and, therefore, burden of headache is significantly correlated with the number of newly diagnosed cases of COVID-19 in Italy. This evidence may hence lead the way to using an infodemiological analysis based on the symptom “headache” for timely predicting future trends of COVID-19 outbreaks.

6.
Int J Infect Dis ; 122: 70-71, 2022 May 20.
Article in English | MEDLINE | ID: covidwho-1851267
8.
9.
EuropePMC; 2021.
Preprint in English | EuropePMC | ID: ppcovidwho-316668

ABSTRACT

Along with identification of clinical or laboratory predictors of unfavorable progression of coronavirus disease 2019 (COVID-19), it is also vital to recognize environmental and hospital indicators that may drive successful management of this illness, thus explaining the heterogeneity of death rates observed across different countries. We retrieved the date of the first diagnosed case and the crude death rate for COVID-19 for each of the European Union (EU) countries from the website of the John Hopkins University, which were then combined with environmental, hospital and clinical indicators extracted from the European Health Information Gateway of the World Health Organization. The COVID-19 death rate in EU countries (mean value 1.9±0.8%) was inversely associated with number of available general hospitals, physicians and nurses. Significant positive associations were also found with rate of acute care beds occupancy, as well as with rate of population aged over 65 years, overweight, and with cancer. Neither total health care expenditure, public-sector health expenditure, or the number of hospital and acute care beds influenced the death rate for COVID-19. These results suggest that some common healthcare system inadequacies such as low number of general hospitals, physicians and nurses, along with high acute care beds occupancy, may be significant drivers of nationwide COVID-19 mortality rates in EU countries.

10.
EuropePMC; 2021.
Preprint in English | EuropePMC | ID: ppcovidwho-315545

ABSTRACT

With the ongoing coronavirus disease 2019 (COVID-19) pandemic continuing across the world, mass screening of severe acute respiratory distress syndrome coronavirus 2 (SARS-CoV-2) infection is a cornerstone of strategies aimed at limiting viral spread within the community. Although mass screening of body temperature with handheld, non-contact infrared thermometers and thermal imagine scanners is now widespread in a kaleidoscope of social and healthcare settings for purpose of detecting febrile individuals bearing SARS-CoV-2 infection, this strategy carries some notable drawbacks, which will be highlighted and discussed in this article. These caveats include the high rate of asymptomatic SARS-CoV-2 infections, the challenging definition of “normal” body temperature, variation of measured values according to the body district, the use of antipyretics, device inaccuracy, impact of environmental temperature, along with the low specificity of this symptom for screening COVID-19 in patients with other febrile conditions. Some pragmatic suggestions will also be endorsed for increasing accuracy and precision of mass screening of body temperature. These encompass the assessment of body temperature (possibly twice) with validated devices, which shall be regularly monitored over time and used following manufacturer’s instructions, the definition of a range of “normal” body temperatures in the local population, patients interrogation on their usual body temperature, standardization of measurement to one body district, allowance of sufficient environmental acclimatization before body temperature check, integration with contact history and other clinical information, as well as exclusion of other possible causes of increased body temperature.

11.
EuropePMC; 2020.
Preprint in English | EuropePMC | ID: ppcovidwho-315544

ABSTRACT

Background: Uncertainty still surrounds the nature and origin of the ongoing coronavirus disease 2019 (COVID-19) pandemic outbreak, especially concerning the most probable date of spill over and worldwide propagation.Methods: An electronic search was carried out on Google Trends, with the Italian search terms “febbre” (fever), “tosse” (cough) and “raffreddore” (cold), which are among the most commonly reported COVID-19 symptoms in Italy. The search period was comprised between June 2019 and February 2020, and was limited to the area of the Lombardia region. The number of national influenza cases was also concomitantly retrieved from the Italian Network of Influenza Surveillance.Results: The trend of Google searches for “febbre” (fever), “tosse” (cough) and “raffreddore” (cold) seemed to mirror that of influenza cases, but only after the second week of November 2020. An unexpected peak of Google searches for these symptoms could be noted between the first week of September and the last week of October. This anomalous volume of Google searches could not be directly attributed to influenza spread. This increase was significantly higher compared to the same period of the previous year 2018 (20.4±15.0%;p=0.020). The volumes of Google searches for the three symptoms were also significantly inter-correlated (correlation coefficients between 0.66-0.83;all p<0.001).Conclusions: The results of our analysis seem to confirm that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may have started to circulate in Italy, and more specifically in the region of Lombardia, earlier before the overt pandemic period, probably already at the beginning of September 2019.

12.
EuropePMC; 2020.
Preprint in English | EuropePMC | ID: ppcovidwho-310426

ABSTRACT

Background. Although the ongoing coronavirus disease 2019 (COVID-19) pandemics is directly contributing to derange global health and fitness, the restrictive measures applied for containing the outbreaks are also impacting detection and management of many diseases, including cancers. This study aimed to establish if and how the COVID-19 outbreak may have impacted the practice of routine prostate cancer screening in Verona, Italy.Methods. We searched the laboratory information system of the Service of Laboratory Medicine of the University Hospitals of Verona to identify all test requests for prostate-specific antigen (PSA) and vitamin D (Vit D;i.e., the most locally requested immunochemical test) for outpatients during the last five years (December 10, 2016, to December 10, 2020). The weekly requests for these tests placed between February 25 and December 9, 2020, was compared to those placed during the period of the previous four years (i.e., 2016-2019).Results. The volume of test requests for both Vit D and PSA did not differ in 2020 compared to the previous four years. However, a dramatic decline was observed during the local lockdown period (between March 10 and May 17, 2020), with a median decrease of 76% for Vit D and 62% for PSA, respectively. This reduction was compensated by 13% increase for Vit D and 43% increase for PSA in the post-lockdown period. Conclusion. These results show that the lockdown period established during the first peak of the COVID-19 outbreak in Italy’s Verona province was associated with a dramatic decrease in routine prostate cancer screening.

13.
The Journal of infection ; 2022.
Article in English | EuropePMC | ID: covidwho-1661274
15.
Eur Geriatr Med ; 13(1): 275-278, 2022 02.
Article in English | MEDLINE | ID: covidwho-1649141

ABSTRACT

PURPOSE: We provide here an updated analysis on efficacy of COVID-19 vaccine booster doses in older people (i.e., aged ≥ 80 years) based on ongoing Italian nationwide COVID-19 vaccination campaign. METHODS: Data were obtained from the COVID-19 national integrated surveillance program, made available and regularly updated by the Italian National Institute of Health. RESULTS: Compared to those who completed the COVID-19 vaccination cycle for ≥ 5 months (n = 2,385,897), those receiving booster doses (n = 1,549,747) had 75% lower risk of SARS-CoV-2 infection, 82-83% lower risk of COVID-19 hospitalization and ICU admission, and 81% lower risk of death. Administration of COVID-19 vaccine boosters generated also greater protection (between 63 and 87% higher) against all these same endpoints compared to early completing (i.e., < 5 months; n = 335,458) a primary COVID-19 vaccination cycle. CONCLUSIONS: The administration of COVID-19 vaccine booster doses is advisable for reducing the risk of morbidity and mortality in older people.


Subject(s)
COVID-19 Vaccines , COVID-19 , Aged , Aged, 80 and over , Humans , Immunization, Secondary , SARS-CoV-2
16.
Eur J Public Health ; 32(2): 328-330, 2022 04 01.
Article in English | MEDLINE | ID: covidwho-1606481

ABSTRACT

We provide here an updated analysis of primary COVID-19 vaccination and vaccine booster doses efficacy, emerging from the ongoing Italian nationwide COVID-19 vaccination campaign. Primary COVID-19 vaccination efficacy was 76-92% within 6 months, decreasing to 34-80% after 6 months. Administration of vaccine booster doses decreased SARS-CoV-2 infections by 65%, COVID-19-related hospitalizations and deaths by 69% and 97% compared with vaccine efficacy after 6 months, but also decreased SARS-CoV-2 infections by 39% compared with vaccine efficacy within 6 months. These results suggest that COVID-19 vaccine booster doses are important for restoring vaccine efficacy and further limiting virus circulation.


Subject(s)
COVID-19 Vaccines , COVID-19 , COVID-19/prevention & control , Humans , Immunization Programs , Immunization, Secondary , SARS-CoV-2 , Vaccination
18.
Diagnosis (Berl) ; 9(1): 11-17, 2021 12 23.
Article in English | MEDLINE | ID: covidwho-1581687

ABSTRACT

The worldwide burden of coronavirus disease 2019 (COVID-19) is still unremittingly prosecuting, with nearly 300 million infections and over 5.3 million deaths recorded so far since the origin of the SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) pandemic at the end of the year 2019. The fight against this new highly virulent beta coronavirus appears one of the most strenuous and long challenges that humanity has ever faced, since a definitive treatment has not been identified so far. The adoption of potentially useful physical preventive measures such as lockdowns, social distancing and face masking seems only partially effective for mitigating viral spread, though efficacy and continuation of such measures on the long term is questionable, due to many social and economic reasons. Many COVID-19 vaccines have been developed and are now widely used, though their effectiveness is challenged by several aspects such as low uptake and limited efficacy in some specific populations, as well as by continuous emergence of new mutations in the SARS-CoV-2 genome, accompanying the origin and spread of new variants, which in turn may contribute to further decrease the effectiveness of current vaccines and treatments. This article is hence aimed to provide an updated picture of SARS-CoV-2 variants and mutations that have emerged from November 2019 to present time (i.e., early December 2021).


Subject(s)
COVID-19 , SARS-CoV-2 , COVID-19/virology , COVID-19 Vaccines , Communicable Disease Control , Humans , Mutation , SARS-CoV-2/genetics
19.
EuropePMC; 2021.
Preprint in English | EuropePMC | ID: ppcovidwho-295434

ABSTRACT

Background: Nationwide COVID-19 (coronavirus disease 2019) vaccination campaigns have been effective to avert as many as 51% deaths in people aged ≥60 years in the European region between December 2020 and November 2021, though broad heterogeneity has been observed in the percentage of averted deaths across the different European countries. Methods: : We downloaded data of vaccine uptake and efficacy into an Excel Worksheet, and we then performed univariate (Spearman’s correlation) and multivariate (multiple linear regression analysis) correlations. Results: : A significant linear association was found between the percentage of averted deaths of older people and percentage of vaccine uptake in each corresponding European country (Spearman’s correlation: r=0.872;p<0.001), though such relationship was even better fitted by using an exponential curve (r=0.881;p<0.001). In multiple linear regression analysis, the percentage of deaths averted by COVID-19 vaccination remained independently associated with vaccine uptake (p<0.001), but not with the type of vaccine administered (p=0.264). Conclusions: : The results of analysis support the foremost importance of reinforcing nationwide COVID-19 vaccination campaigns, especially in those countries where vaccination programmes have been less successful.

20.
EuropePMC; 2021.
Preprint in English | EuropePMC | ID: ppcovidwho-295316

ABSTRACT

We provide here an updated analysis of primary COVID-19 vaccination and vaccine booster doses efficacy, emerging from the ongoing Italian nationwide COVID-19 vaccination campaign. Primary COVID-19 vaccination efficacy was 76-92% within 6 months, decreasing to 34-80% after 6 months. Administration of vaccine booster doses decreased SARS-CoV-2 infections by 65%, COVID-19 related hospitalizations and deaths by 69% and 97% compared to vaccine efficacy after 6 months, but also decreased SARS-CoV-2 infections by 39% compared to vaccine efficacy within 6 months. These results suggest that COVID-19 vaccine booster doses are important for restoring vaccine efficacy and further limiting virus circulation.

SELECTION OF CITATIONS
SEARCH DETAIL